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Aims: The ATP-binding cassette (ABC)G2 transporter protects the heart from
pressure overload-induced ventricular dysfunction but also protects cancer cells from
chemotherapeutic agents. It is upregulated in the myocardium of heart failure patients
and clears hypoxia-induced intracellular metabolites. This study employs ABCG2
knockout (KO) mice to elucidate the relevance of ABCG2 for cardiac and pulmonary
vascular structure and function in chronic hypoxia, and uses human primary cardiac
fibroblasts to investigate the potential role of ABCG2 in cardiac fibrosis.
Methods and results: ABCG2 KO and control mice (n= 10) were subjected to 4 weeks
normoxia or hypoxia. This allowed for investigation of the interaction between genotype
and hypoxia (GxH). In hypoxia, KO mice showed pronounced right (RV) and left (LV)
ventricular diastolic dysfunction. Compared to normoxia, end-diastolic pressure (EDP)
was increased in control vs. KO mice by +1.1 ± 0.3 mmHg vs. +4.8 ± 0.3 mmHg, p for
GxH < 0.001 (RV) and +3.9 ± 0.5 mmHg vs. +11.5 ± 1.6 mmHg, p for GxH = 0.110
(LV). The same applied for myocardial fibrosis with +0.3 ± 0.1% vs. 1.3 ± 0.2%, p
for GxH = 0.036 (RV) and +0.06 ± 0.03% vs. +0.36 ± 0.08%, p for GxH = 0.002 (LV),
whereas systolic function and capillary density was unaffected. ABCG2 deficiency did not
influence hypoxia-induced pulmonary hypertension or vascular remodeling. In line with
these observations, human cardiac fibroblasts showed increased collagen production
upon ABCG2 silencing in hypoxia (p for GxH = 0.04).
Conclusion: Here we provide evidence for the first time that ABCG2 membrane
transporter can play a crucial role in ventricular dysfunction and fibrosis in
hypoxia-induced pulmonary hypertension.
Keywords: ABC transporters, right ventricular function, hypoxia, diastolic dysfunction, ventricular fibrosis,
pulmonary hypertension
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INTRODUCTION
Right ventricular (RV) failure is the main cause of premature
death of patients with pulmonary hypertension (PH) (Bogaard
et al., 2009; Paulin et al., 2015). Despite a growing body
of evidence on molecular mechanisms of RV failure, there
are abundant unknown pathways and factors needed to be
identified. RV dysfunction is commonly seen as a consequence
of chronic RV pressure overload and a developing imbalance of
RV oxygen demand and supply with neurohormonal activation
and abnormal energy metabolism (Sano et al., 2007; Bogaard
et al., 2009; Tuder et al., 2012; Voelkel et al., 2012; Vonk-
Noordegraaf and Westerhof, 2013; Paulin et al., 2015). But there
are also structural changes with myocardial fibrosis as the most
striking feature that is strongly associated with RV dysfunction
and prognosis.
ABC transporters are active transmembrane proteins capable
tomove a wide variety of substrates across extra- and intracellular
membranes thereby modulating cell metabolism and cellular
toxicity (Dean et al., 2001). Recent study shows, that knock
out or inhibition of ABCC4 transporter (also known as MRP4)
prevents and reverses hypoxia-induced pulmonary hypertension
in mice (Hara et al., 2011). Similarly to ABCC4, another ABC
transporter family member, the ABCG2 is transcriptionally
regulated by hypoxia-inducible transcription factor (HIF) and
exports endogenous toxicmetabolites that are induced by chronic
hypoxia, thereby preventing their intracellular retention (Jonker
et al., 2002; Krishnamurthy et al., 2004; Zhou et al., 2005).
Loss of ABCG2 results in an accumulation of porphyrins,
and haeme degradation products and portends poor survival
under hypoxia (Krishnamurthy et al., 2004). The expression of
ABCG2 transporter was predominantly localized to the capillary
endothelial cells, and cardiomyocytes in the heart (Solbach et al.,
2008; Higashikuni et al., 2010). In heart failure, the left ventricular
expression of the ABCG2 transporter is strongly elevated and
correlates with atrial natriuretic peptide (ANP) (Solbach et al.,
2008). In addition, ABCG2 protects against pressure overload-
induced cardiac hypertrophy and left heart failure (Higashikuni
et al., 2012) and is cardioprotective after myocardial infarction
(Higashikuni et al., 2010). These findings suggest that ABCG2 is
an important protective factor for the myocardium, particularly
under conditions of chronic myocardial hypoxia like ischemic
heart disease or lung disease with hypoxemia.
In the clinical setting, ABCG2 is also known as Breast
Cancer Resistance Protein (BCRP), as one of the major factors
causing drug resistance in cancer cells (Szakacs et al., 2006;
Wu et al., 2008). ABCG2 transports many different substrates,
providing resistance against multiple chemotherapeutic agents.
Therefore, ABCG2 has been considered as an important target
in cancer treatment to improve sensitivity for chemotherapy
(Breedveld et al., 2006; Hardwick et al., 2007) and ABCG2
inhibitors have been tested in clinical studies(Kruijtzer et al.,
2002; Kuppens et al., 2007; Molina et al., 2008). Such new drug
developments necessitate a thorough investigation of the role of
the molecular target not only under physiological but also under
stress conditions which are commonly present in cancer patients
with their main comorbidities.
In this study, we explored the role of ABCG2 in hypoxia-
induced remodeling of the right ventricle. We provide evidence
that under chronic hypoxia, loss of ABCG2 leads to biventricular
fibrosis with diastolic dysfunction, without affecting RV
afterload, capillary density or hypoxia-induced pulmonary
vascular remodeling.
METHODS
Animals
Male ABCG2 global knockout (KO) mice (FVB/N) were
purchased from Taconic Europe (Laven, Denmark). We applied
the chronic hypoxic mouse model, a routinely used method in
various research fields (Gamboa and Andrade, 2010; Crnkovic
et al., 2016), which allows the investigation of the effects of
hypoxia. The experimental condition of 10% oxygen corresponds
to a height of about 5,000m. For the hypoxia-induced pulmonary
hypertension group 10–12 week old mice (10 wild type (WT)
and 11 KO per group) were placed in normobaric 10% hypoxic
chambers [fraction of inspired oxygen (FiO2) of 0.10] for 4
weeks. Control mice were kept in normobaric normoxia (FiO2
of 0.21). Oxygen concentration was monitored and maintained
continuously using the OxyCycler system (BioSpherix, Lacona,
NY, USA). ABCG2 KO mice and WT animals were kept
under conventional conditions on chow-fed diet. Chambers
were opened twice per week for feeding and cleaning. All
experiments were approved by the Federal Ministry of Science
and Research (Austria), according to national regulations
(Austrian Ministry of Education, Science and Culture, BMWF-
66.010/0062-II/3b/2012).
Haemodynamic Measurements
Heart catheterization was performed under constant inhalation
of 2% isoflurane-oxygen narcosis, using the closed chest
technique through a small incision on the submandibular area, as
described previously (Crnkovic et al., 2011). The right ventricle
(RV) was catheterized via the right jugular vein and pressures
were monitored continuously in order to determine the position
of the catheter. After data collection from the right heart, a
catheter was inserted into the right carotid artery where blood
pressure was measured, and then advanced into the left ventricle
where pressures were also recorded. Left ventricular pressure
measurements—demanding an additional vascular access from
the carotis—were performed after data collection from the right
ventricle, which is a laborious procedure. In certain animals, by
the time of left ventricular measurements the haemodynamic
system became unstable, therefore they were excluded from the
analysis. Furthermore, in some animals the quality of pressure
recording was not sufficient to measure precise LVEDP or
RVEDP (and Tau, mindP/dt, maxdP/dt) by the applied analysis
module of the software.
Data was collected using SPR-671 1.4F catheters (Millar
Instruments Inc., Houston, TX, USA) coupled to a Millar PCU-
2000 pressure control unit and PowerLab 8/30 acquisition system
(AD Instruments, Spechbach, Germany) with a sampling rate
of 1 kHz. Before insertion into the vein, the catheter was
placed into a small horizontal fluid-filled tube and calibrated
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to atmospheric pressure (accuracy 0.1 mmHg). Recordings
were made over a 2-min period and analyzed with Powerlab
Pro Software (AD Instruments, Spechbach, Germany). End-
diastolic pressure (EDP), Tau index [Tau∗Correspondent heart
rate (Supplementary Figure S1)], mindP/dt and maxdP/dt were
calculated from pressure tracings using a software analysis
module.
Assessment of Right Heart Hypertrophy
Following haemodynamic measurements, animals were
exsanguinated, lungs and hearts were perfused via the right
ventricle with phosphate buffered saline. The heart was dissected
free and kept on ice in PBS solution. After removing the atria
from the heart, the right ventricle (RV) was dissected from the
left ventricle plus septum (LV+S) and the separated regions
were weighed to obtain the ratio of the right heart to the left
ventricle plus septum [RV/(LV+S)] or to the animal’s body
weight (RV/BW).
Pulmonary Arterial Banding
The pulmonary arterial banding (PAB) surgery was performed
as previously described (Egemnazarov et al., 2015). Mice were
anesthetized with intra-peritoneal fentanyl 0.05 mg/kg and
midazolam 5 mg/kg and anesthesia was maintained with 2–
3% isoflurane. After orotracheal intubation, the mice were
mechanically ventilated using a volume controlled small animal
ventilator MiniVent Type 845 (Hugosachs, March-Hugstetten,
Germany). Ventilation settings were adjusted according to body
mass using formulas (Tarnavski et al., 2004): Vt(ml) = 6.2 ×
M(kg)ˆ1.01, where Vt(ml) is tidal volume and M(kg) is body
mass of animal; and RR(min−1) = 53.5 × M(kg)ˆ−0.26, where
RR(min−1) is ventilation rate. A mouse weighing 25 g was
ventilated with tidal volume of 150 µl and ventilation rate of 140
breaths/min.
An incision wasmade in the second left intercostal space using
sterile technique, the pericardium was removed, and a partially
occlusive titanium clip was placed around the main pulmonary
artery (Weck, Research Triangle Park, NC, USA). The pulmonary
artery was occluded to 0.3mm, which approximately corresponds
to 75% occlusion of the lumen diameter. The mice were then
sutured and allowed to recover from anesthesia. Post-operative
analgesic therapy was achieved by a subcutaneous injection of
buprenorphine 0.1 mg/kg every 24 h for 3–5 days depending on
animal’s condition. Sham-treated animals underwent the same
procedure with a vascular clip placed next to the vessel.
Immunohistochemistry
Right lung was perfusion-fixed through the trachea with 4%
formalin and embedded into paraffin blocks. The isolated
heart was dissected in order to determine hypertrophy and
processed also into paraffin for sectioning. Formalin-fixed
paraffin-embedded lung and heart tissue was cut to 3,5 µm
thick sections and stained with Masson’s trichrome to determine
collagen content. The level of fibrosis in right ventricle, in
left ventricle + septum and around pulmonary vessels was
quantified on the whole specimen area using image analysis
software (Visiopharm, Hoersholm, Denmark). Antigen retrieval
was performed with 0,01 M sodium citrate solution (pH 6.0)
in 95◦C. Duplicates were processed without primary antibodies
as controls. ABCG2 protein expression was detected with
anti-BCRP1/ABCG2 antibody (#AV43649, Sigma-Aldrich, Saint
Louis, USA). Quantitative assessment of capillary density in the
right heart and in left ventricle + septum was identified by anti-
thrombomodulin (#AF3894, R&D systems, Minneapolis, USA)
staining. The number of capillaries was reported relative to the
total sample area in each case.
Image Analysis
Immunostained sections were digitized using slide scanner
(Aperio, Oxford, UK) with an objective of 40× magnification.
Digital image analysis was carried out by using Visiopharm
Integrator System (VIS) semi-automated image analysis software,
version 4.2.9.0. (Visiopharm, Hoersholm, Denmark).
Cardiac Fibroblast Isolation
Mouse cardiac fibroblasts were isolated using a combined
method of mechanical disruption and enzymatic digestion with
collagenase buffer. Briefly, hearts from 9 weeks old (FVB/N)
mice were removed and perfused with 1 ml of collagenase buffer
(Krebs-Ringer buffer + 0.5 mg/ml collagenase II, 2.5 mM CaCl2
and 1 mg/ml BSA) in a retrograde manner from the aorta.
The hearts were dissected free of connective tissue, vessels and
atria. Right ventricles were carefully dissected, left ventricles were
opened, and both were washed free of blood. 3-3 right- and
left ventricles were combined and transferred into collagenase
buffer where minced into small pieces. In between 3 rounds
of digestion step (6 min/37◦C), tissue pieces were triturated
repeatedly with pipetting until no visible tissue fragments could
be observed. Cell suspensions were collected and plated in T75
tissue culture flasks in DMEM/F-12 (1:1) (#21001-020, Gibco by
life technologies, Paisley, UK) medium supplemented with 10%
FCS, 1% L-glutamine and antibiotic-antimycotic solution. The
medium was changed after 3 h, adherent cells were cultivated till
∼90% confluency, when cells were detached using 0.25% (w/v)
trypsin/EDTA, and recultured until passage 3 for experiments.
The purity of the isolated cells was validated by an expression
panel of characteristic fibroblast markers.
Lung Fibroblast Isolation
Mouse lung fibroblasts were isolated using a mechanical
disruptionmethod. Briefly, lungs from 9weeks old (FVB/N)mice
were removed, dissected free of connective tissue, trachea and
large vessels. After washing free of blood, lungs of 3 animals were
combined, cut into small pieces and passed through a 100 µm
mesh to avoid bigger vessels and bronchii. Cell suspensions were
collected and plated in T75 tissue culture flasks in DMEM/F-
12 (1:1) (#21001-020, Gibco by life technologies, Paisley, UK)
medium supplemented with 10% FCS, 1% L-glutamine and
antibiotic-antimycotic solution. The medium was changed after
2 days, adherent cells were cultivated till ∼90% confluency,
when cells were detached using 0.25% (w/v) trypsin/EDTA,
and recultured until passage 3 for experiments. The purity
of the isolated cells was validated by an expression panel of
characteristic fibroblast markers.
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Cell Culturing, Cell Stimulation
Human cardiac fibroblasts from the ventricle were obtained from
Promocell. All experiments were performed with human cells
in passage two to seven grown in complete fibroblast medium
(Fibro Life R© S2) or with mouse fibroblasts in passage 3 cultured
in DMEM/F-12 (1:1) (10% FCS, 1% L-glutamine, 0.2% P/S).
Prior to all stimulations, cells were kept in quiescent medium
(VascuLife R© Basal Medium 0%FCS with 1% P/S, or DMEM/F-
12 (1:1) 0%FCS with 0.2% P/S for mouse fibroblasts) for 12
h, whereas treatments were performed in medium containing
2% FCS (VascuLife R© Basal Medium 2% FCS with 1% P/S or
DMEM/F-12 (1:1) 2%FCS with 0.2% P/S for mouse fibroblasts).
A target-specific siRNA sequence, directed against human or
mouse ABCG2 was purchased from Santa Cruz Biotechnology
(#sc-41151 (h), #sc-37054 (m), Santa Cruz Biotechnology,
Heidelberg, Germany). As control, a negative-control siRNA
sequence was employed (#sc-37007, Santa Cruz Biotechnology,
Heidelberg, Germany). Cells were transfected with siRNA using
Amaxa Basic Nucleofector Kit (#VPI-1002, Lonza, Cologne,
Germany). The siRNA-mediated down-regulation of the target
protein was assessed 48 h after transfection by quantitative
PCR and western blotting. Hypoxic treatment of the cells
were carried out in an hypoxic work station from Biospherix
(BioSpherix, Lacona, NY, USA) using fully-integrated incubators
and work station with dynamic programmable hypoxic and non-
condensing humidity control at 37◦C. Hypoxic exposure (FiO2
of 0.01) was used for 48 h.
Immunofluorescence
Mouse heart sections were deparaffinised at 60◦C for 2 h,
and incubated with 0.17% (w/v) trypsin for 20 min at 37◦C,
followed by blocking with 10% BSA in PBS for 40 min.
Then samples were incubated overnight at 4◦C with anti-
ABCG2 (#AV43649, Sigma-Aldrich, 1:100 in 10% BSA) and
anti-Vimentin (Abcam #ab11256, 1:200 in 10% BSA) antibodies,
followed by incubation with Alexa Fluor 488 and 555-labeled
antibodies for 45 min at room temperature (Life Technologies,
1:500 in 0.1% BSA). Sections were counterstained with
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma-
Aldrich) to identify nuclear DNA. For control staining duplicates
were processed without primary antibodies.
Fibroblasts were grown on eight-well chamber slides and
fixed by addition of 4% paraformaldehyde for 20 min at
37◦C. Fixed cells were rinsed three times with PBS then
permeabilized with 0.1% Triton-X100 in PBS for 15 min
at room temperature followed by blocking with 3% BSA in
PBS for 30 min. Then the cells were incubated overnight
at 4◦C with anti-ABCG2 (Abcam #ab3379, 1:100 in PBS),
anti-Fibronectin (Abcam #ab23750, 1:100 in 0.1% BSA), anti-
Vimentin (Abcam #ab11256, 1:400 in 0.1% BSA), anti-Periostin
(Abcam #ab14041, 1:200 in 0.1% BSA), anti-S100A4 (Abcam
#ab27957, 1:200 in 0.1% BSA) or anti-F-actin (Life technologies
#A34055-conjugated, 1:80 in 0.1% BSA) antibodies respectively,
followed by incubation with Alexa Fluor 555-labeled secondary
antibodies (Life Technologies, 1:1,000 in PBS, except F-actin)
for 30 min at room temperature. Cells were counterstained with
DAPI (Sigma-Aldrich) to identify nuclear DNA. For control
staining duplicates were processed without primary antibodies.
Images were taken using Olympus Basic BX61VS Fluorescence
microscope at magnification of×40.
Proliferation Assay
Human cardiac fibroblasts were silenced as described above,
later seeded in 96 well plates 20,000 cells/well. The following
day media was changed to VascuLife R© Basal Medium (2%
FCS, 1% P/S) preincubated for 12 h in a hypoxic chamber,
and the cells were placed in hypoxia (FiO2 of 0.01). After
24 h, preincubated VascuLife R© Basal Medium (2% FCS,
1% P/S) was administered together with 2 µCurie/ml [3H]-
thymidine (American Radiolabeled Chemicals, St.Louis, USA).
Proliferation rate was determined by thymidine incorporation
after 24 h as an index of DNA synthesis, measured as
radioactivity by radioactive scintillation counter (Wallac
1450 MicroBetaTriLux, Minnesota, USA). Experiments were
performed in quintuplicates.
Hydroxyproline Assay
Silenced human or mouse fibroblasts were seeded in 6 well
plates, 200,000 cells/well. The following day, media was changed
to VascuLife R© Basal Medium (2% FCS, 1% P/S for human
cells) or DMEM/F-12 (1:1) (2%FCS with 0.2% P/S for mouse
fibroblasts) medium preincubated for 12 h in a hypoxic chamber,
and cells -treated by this preconditioned media- were placed
in hypoxia (FiO2 of 0.01) for 48 h. Later, cells were harvested
and protein samples were hydrolysed in 6 M HCl at 95◦C
for 20 h. Following incubation, the tubes were cooled to
room temperature and centrifuged for 10 min at 13,000 ×
g. Supernatants were×incubated with the detection reagents
provided in the kit (Quickzyme Biosciences, Leiden, The
Netherlands) at 60◦C for 2 h and plate was read at 570 nm using
spectrophotometer.
Western Blot Analysis
Protein extracts of mouse ventricles or fibroblasts were prepared
in RIPA buffer containing protease-inhibitor and phosphatase-
inhibitor tablets (Roche, Vienna, Austria). After mechanical
disruption of tissue samples, equivalent amounts of protein were
separated on a SDS polyacrylamide gel, followed by electro-
transfer to nitrocellulose membrane. Nonspecific antibody
binding was blocked by incubation in 5% (m/v) non-fat dry
milk powder in TBS-T (20 mM Tris-Cl, pH 7.5, 150 mMNaCl,
0.1% (v/v) Tween 20) at room temperature for 1 h. Then,
samples were incubated overnight at 4◦C with antibodies:
anti-ABCG2 (#ab3380, Abcam) and anti-α-tubulin (#ab4074,
Abcam) for ventricular tissues, and anti-ABCG2 (#AV43649,
Sigma-Aldrich, Saint Louis, USA) and anti-GAPDH (#sc-25578,
Santa Cruz Biotechnology, Heidelberg, Germany) for fibroblasts.
After 1 h incubation in room temperature with peroxidase-
labeled secondary antibody (Pierce Biotechnology, Rockford,
USA), specific immunoreactive signals were detected using
Enhanced ChemiLuminescence kit (Amersham Biosciences,
Buckinghamshire, UK) or West Pico Substrate (Thermo
Scientific, Rockford, USA).
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RNA Extraction and Quantitative
Real-Time (Q-)PCR Analysis
RNA was extracted from mouse formalin-fixed paraffin-
embedded ventricle samples, using RNeasy FFPE Kit (#73504,
Qiagen, Hilden, Germany). From cells RNA was extracted using
spin-columns of peqGOLD Total RNA isolation kit (PeqLab,
Erlangen, Germany). Nanodrop 2000c spectrophotometer
(Nanodrop, Rockland, USA) was used to quantify the
concentration and the purity of the isolated total RNA.
Extracted RNA was reverse transcribed using iScript cDNA
Synthesis Kit (BioRad, CA, USA). The final reaction mixture was
incubated for 5 min at 25◦C, followed by 30 min at 42◦C and
the reaction was terminated by heating at 85◦C for 5 min. The
reverse transcription reaction product was directly used in the
PCR reaction or stored at−20◦C. Gene expression was measured
by quantitative real time PCR analysis using QuantiFast
SYBR PCR Kit (Qiagen, Hilden, Germany). Reaction mixtures
contained SYBR Green mastermix, forward plus reverse primers
(Supplementary Table S1), and cDNA samples. Amplification
was quantified with Lightcycler 480 system (Roche) using the
next protocol: 1 × (95◦C, 5 min); 40 × (95◦C, 10 s; 60◦C, 30
s). The data for amplification curves were acquired after the
extension phase at 60◦C. After amplification, melting curves were
analyzed for validating PCR products. Genes were measured in
duplicates. The expression of targeted genes are shown as 1CT
values normalized to the level of Beta-2 microglobulin (B2 mg)
housekeeping gene using the averaged CT values by the formula
1CT= CT(Housekeeping Gene)—CT(Gene of Interest).
Cytokine and Chemokine Measurements
Circulating cytokine and chemokine profiling was performed
on blood-derived serum samples from hypoxia-treated WT and
ABCG2 KO mice (n:4 WT and 4 KO) using a dedicated mouse
cytokine array kit (#ARY006, R&D systems, Minneapolis, USA).
The array was performed according to manufacturer’s protocol.
Briefly, 50 µl serum samples were mixed with the provided
biotinylated antibody cocktail, then incubated overnight (4◦C)
with the array nitrocellulose membrane containing duplicates of
antibody spots against the chemokines. The chemiluminescent
signal produced in the following step was proportional to the
amount of captured cytokines. Developed X-ray films were
analyzed using ImageJ software (Bethesda, Maryland, USA).
Correspondent pixel densities are shown as arbitrary units
normalized to the given reference spots of the membranes.
Statistical Analysis
Numerical values are given as means± SD for all measurements.
Statistical analysis was performed with SPSS Statistics software
(IBM, USA: SPSS Inc.) and GraphPad Prism 5. Differences
according to the genotype (KO vs. WT) and the treatment
(normoxia vs. hypoxia) and their interactions (GxH) were
analyzed by adjusted rank transformed two-way ANOVA (Leys
and Schumann, 2010). Due to the exploratory character of the
study, no p-value adjustment was applied for the analysis of
main effects and interactions in the different parameters. For
post hoc analysis of the interaction, KO and WT mice were
compared separately in both treatment (normoxia vs. hypoxia),
and normoxia vs. hypoxia were compared separately within
both genotypes using Bonferroni adjusted Mann-Whitney U
Test (four comparisons). For comparison of two groups, Mann-
Whitney U test was carried out (p < 0.05 were considered
significant). In the figures, only the results of the applied
post hoc analysis or the Mann-Whitney U test are shown to
provide information about intergroup contrasts. The general
effect of hypoxia and genotype is presented in the adjusted rank
transformed two-way ANOVA Supplementary Table S2.
RESULTS
ABCG2 Knockout Has No Influence on
Hypoxia-Induced Pulmonary Hypertension
In normoxia, RVSP, LVSP, systolic blood pressure, Fulton index
[RV/(LV+S)] and hematocrit showed no differences between the
two genotypes. RVSP, Fulton index and hematocrit increased in
response to chronic hypoxia, independent of genotype, indicating
that the development of hypoxic pulmonary hypertension was
not affected by ABCG2. There were no interactions of hypoxia
and genotype in any of these parameters (Figures 1A–F).
Significant Diastolic Dysfunction in ABCG2
KO Mice in Response to Hypoxia
Representative RV pressure recordings obtained from right
heart catheterisation are shown from wild type (WT) and
ABCG2 knockout (KO)mice under hypoxia in Figure 2A. Under
normoxic conditions, the pressure of the right ventricle at the
end of diastole (RVEDP) did not differ significantly between
KO and WT mice (1.12 ± 0.29 mmHg vs. 1.69 ± 0.12 mmHg)
(Figure 2B). Hypoxia caused a significant increase in RVEDP in
both WT and KO mice, compared to the respective normoxic
controls (p < 0.001, Supplementary Table S2). However, the
effects were significantly stronger in KO than in WT mice as
demonstrated by the interaction of the factors hypoxia and
genotype (p for interaction < 0.001, Figure 2B). Thus hypoxia
caused diastolic dysfunction in KO mice. The time constant
of ventricular pressure decay [Tau (τ)] did not differ between
any of the experimental groups (Figure 2C), indicating that the
diastolic dysfunction was mainly relevant in the late diastolic
phase. There was decreased mindP/dt in hypoxia independent of
genotype (p< 0.001, Figure 2D). This is consistent with hypoxic
pulmonary vasoconstriction causing larger pressure decay during
early diastole. Similarly an increase was observed with maxdP/dt
(Figure 2E, Supplementary Table S2).
Left ventricular end-diastolic pressure (LVEDP) of WT and
KO mice did not differ in normoxia but hypoxia caused
an elevation (p = 0.001, Supplementary Table S2). Although
the effect was more pronounced in KO mice, the interaction
between hypoxia and genotype did not reach significance (p for
interaction = 0.11, Figure 3B), which might be due to lower
sample sizes in these groups. In the left ventricle hypoxia had
a significant effect on mindP/dt independent of genotype (p =
0.013, Figure 3D). However, neither the genotype nor hypoxia
had any significant effects on Tau or maxdP/dt (Figures 3C,E,
Supplementary Table S2).
Frontiers in Physiology | www.frontiersin.org 5 February 2017 | Volume 8 | Article 98
Nagy et al. ABCG2 in Biventricular Dysfunction
FIGURE 1 | Knocking out ABCG2 does not influence hypoxia-induced pulmonary hypertension. Bar graphs summarize (A) right ventricular systolic pressure
(RVSP) (n = WT nox:9, WT HOX:9, KO nox:10, KO HOX:11), (B) left ventricular systolic pressure (LVSP) (n = WT nox:8, WT HOX:8, KO nox:5, KO HOX:7) and (C)
systolic blood pressure (SBP) (n = WT nox:9, WT HOX:9, KO nox:5, KO HOX:11) of WT and ABCG2 KO mice exposed to normoxia or chronic hypoxia. (D) Right
ventricular hypertrophy shown by right ventricular (RV) to left ventricular plus septum (LV+S) ratio) (n = WT nox:9, WT HOX:10, KO nox:11, KO HOX:11) and (E) RV to
body weight (BW) ratio (n = WT nox:9, WT HOX:10, KO nox:11, KO HOX:11). Percentage of blood haematocrit (Hct) levels in mice after normoxia or chronic hypoxia
shown in subset (F) (n = WT nox:7, WT HOX:7, KO nox:7, KO HOX:7). Bar graphs represent values as means ± SD (* corresponds to hypoxic treatment within
genotype; *p < 0.05, **p < 0.01, ***p < 0.001).
Increased Ventricular Fibrosis in ABCG2
KO Mice under Hypoxia, without Changes
in Capillary Density
Under normoxia, there were no differences in the RV
(Figures 4A,B) and LV (Figures 4C,D) fibrosis scores of KO
mice compared to WT. Hypoxia caused a significant increase
in ventricular fibrosis scores in KO, but not in WT mice. This
was true for the right (p for interaction < 0.05) and for the left
ventricle (p for interaction < 0.01). Figure 4 shows that fibrosis
was more pronounced in the RV but the response pattern in
terms of hypoxia and genotype was the same in both ventricles.
The observed increase in RV fibrosis correlated significantly with
RVEDP (p < 0.05, R2 = 0.59, see Supplementary Figure S2). On
the other hand, neither hypoxia, nor the lack of ABCG2 had any
significant effect on lung fibrosis (Figures 4E,F).
Previous studies in the transverse aortic constriction model
showed that mice lacking ABCG2 have reduced angiogenesis
in the LV, which was associated with cardiac hypertrophy
(Higashikuni et al., 2010, 2012). To investigate the involvement of
ABCG2 on the capillary density, we stained for thrombomodulin
to visualize capillaries in RV and LV sections (see Supplementary
Figure S3). Interestingly, neither hypoxia, nor the lack of ABCG2
had any effect on ventricular capillary density (see Supplementary
Figures S3B,C, Supplementary Table S2). This indicates that
the observed EDP elevation and ventricular fibrosis may occur
completely independent of vessel density.
Fibrosis-Related Genes in Ventricular
Tissue of Hypoxic Mice
The expression profile of fibrosis-related molecular markers in
the RV and LVwas investigated by Q-PCR, in order to investigate
ongoing fibrotic processes (see Supplementary Figure S4). At the
end of 4 weeks hypoxic treatment, when myocardial fibrosis was
already established, there were no significant changes in most
of the investigated genes. In the RV, Col3A1 was significantly
upregulated in ABCG2 KO mice in hypoxia (p < 0.05). This
could be due to both, hypoxia or increased RV afterload, however,
as there was no such increase in the LV, this indicates that
the ongoing upregulation was mainly due to the persistently
increased afterload in the case of the RV.
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FIGURE 2 | Exacerbated right ventricular diastolic dysfunction in ABCG2 knockout mice in response to hypoxia. (A) Representative pressure curves
showing right ventricular pressure recordings, illustrating (arrows) end-diastolic pressure (RVEDP) alterations in ABCG2 KO (dashed line) compared to WT mice
(continuous) under hypoxia. Summarized haemodynamic parameters showing (B) RVEDP (n = WT nox:7, WT HOX:7, KO nox:7, KO HOX:7), (C) Tau index (n = WT
nox:6, WT HOX:7, KO nox:7, KO HOX:7), (D) mindP/dt (n = WT nox:7, WT HOX:7, KO nox:7, KO HOX:7) and (E) maxdP/dt (n = WT nox:7, WT HOX:7, KO nox:7,
KO HOX:7) obtained from right ventricle of ABCG2 KO and WT mice exposed to normoxia or chronic hypoxia. Bar graphs represent values as means ± SD
(Interaction p corresponds to hypoxia·genotype interaction, #corresponds to difference between genotypes in hypoxia, * corresponds to hypoxic treatment within
genotype; *p < 0.05, **p ##p < 0.01).
Increased Extracellular Matrix Production
in ABCG2 Silenced Mouse Isolated Cardiac
Fibroblasts under Hypoxia
As shown in Figure 5A, ABCG2 was coexpressed with
vimentin—fibroblastic marker in mouse ventricular tissue.
Cardiac fibroblasts (see Supplementary Figure S5) derived from
mouse right- (Figure 5B) and left ventricles (Figure 5C) showed
increased collagen production in the absence of ABCG2 under
hypoxia (p < 0.05). On the other hand, silencing of ABCG2
did not affect the extracellular matrix production of mouse
primary lung fibroblasts in hypoxia (Figure 5D). These results
suggest that in hypoxic mouse ventricular fibroblasts, -but not in
pulmonary fibroblasts- ABCG2 protects against excess collagen
production.
Increased Extracellular Matrix Production
in ABCG2 Silenced Human Primary Cardiac
Fibroblasts under Hypoxia
In human primary cardiac fibroblasts, the readouts were
proliferation and the collagen production. Human cardiac
fibroblasts expressed ABCG2 protein (Figures 6A,B). The
efficiency of our siRNA against ABCG2 was quantified on the
mRNA and protein level, and showed nearly 80% silencing
(Figure 6B). Silencing of ABCG2 did not change primary
cardiac fibroblast proliferation under normoxia or hypoxia
(Figure 6C). However, when ABCG2 was supressed in human
cardiac fibroblasts there was an increased collagen production
under hypoxia showing significant interaction between ABCG2
silencing and treatment (p for interaction < 0.05, Figure 6D).
This indicates that in human primary cardiac fibroblasts,
ABCG2 plays a protective role against hypoxia-induced collagen
production.
Regulation of ABCG2 in the Stressed
Mouse Ventricle
ABCG2 expression was significantly increased in the RV of
chronic hypoxia-treated mice (p < 0.05, Figures 7A,B) but not
in the hypoxic left ventricle (Figures 7C,D). Upregulation of
the ABCG2 gene was observed in RVs of pulmonary artery
banded mice (p< 0.01, see Supplementary Figure S6), suggesting
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FIGURE 3 | Left ventricular diastolic dysfunction in ABCG2 knockout mice in response to hypoxia. (A) Representative pressure curves showing left
ventricular pressure recordings, illustrating (arrows) end-diastolic pressure (LVEDP) alterations in ABCG2 KO (dashed line) compared to WT mice (continuous) under
hypoxia. Summarized haemodynamic parameters showing (B) LVEDP, (C) Tau index, (D) mindP/dt, and (E) maxdP/dt obtained from left ventricle of ABCG2 KO and
WT mice exposed to normoxia or chronic hypoxia. (n = WT nox:5, WT HOX:7, KO nox:5, KO HOX:6) Bar graphs represent values as means ± SD (*corresponds to
hypoxic treatment within genotype; *p < 0.05).
that after chronic hypoxic exposure, afterload but not hypoxia
regulates ABCG2 in the myocardium.
DISCUSSION
The present study investigated the role of the ABC membrane
transporter family member ABCG2 in hypoxia on cardiac and
pulmonary vascular function. Our results show, that ABCG2
knockout mice developed significant biventricular diastolic
dysfunction and fibrosis under chronic hypoxia. In contrast,
ABCG2 KO animals showed lung vascular remodeling, increased
pulmonary pressure and RV hypertrophy similar to WT mice,
thus the absence of ABCG2 had no influence on the development
of hypoxia-induced PH. These results may help in understanding
the protective role of ABCG2 for function and structure of the
heart under hypoxic conditions and raise some concern against
the use of specific inhibitors for cancer therapy.
Exposure of mice to chronic hypoxia causes many of the
anatomic and haemodynamic alterations of the lung and the
heart that are known from patients with chronic lung disease
(Stenmark et al., 2009; Ryan et al., 2011), thus recapitulates
the human chronic hypoxemic conditions. After development
of pulmonary arterial remodeling, the RV has to cope with
an increased afterload which initially results in the elevation
of systolic and diastolic ventricular pressures, leading to RV
hypertrophy and finally to RV decompensation (Leite-Moreira
et al., 1999; Humbert et al., 2004; Martos et al., 2007; Vonk
Noordegraaf and Galie, 2011; van de Veerdonk et al., 2011;
Paulin et al., 2015). We found significantly increased ABCG2
levels in the right- but not the left ventricles of hypoxic animals.
In chronic hypoxic pulmonary hypertensive mice the RV had to
adapt to persistently increased afterload in addition to hypoxia.
This might be the reason why gene expression differences could
be detected only in the RV at the end of the hypoxic exposure,
indicating a putative role of this transporter in the stressed heart.
This notion is also supported by an increased ABCG2 expression
in the RV of pulmonary arterial banded (PAB) mice (see
Supplementary Figure S6), an animal model recapitulating
solely RV pressure overload observed in pulmonary
hypertension.
Incomplete ventricular relaxation at end-diastole causes
elevated filling pressure which is the main characteristic of
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FIGURE 4 | Increased ventricular fibrosis in ABCG2 KO mice under hypoxia. (A) Masson’s trichrome staining shows presence of collagen (blue) in right
ventricular sections of ABCG2 KO and WT mice after normoxic or hypoxic exposure. The same is shown for the left ventricle (C), and in lung tissue in subset (E).
Quantification shows presence of collagen in the right- (B) and left ventricle (D), as well as in the lung (F). (n = WT nox:6, WT HOX:7, KO nox:7, KO HOX:7) Scale bar
indicates 50 µm. Bar graphs represent values as means ± SD (Interaction p corresponds to hypoxia·genotype interaction, #corresponds to difference between
genotypes in hypoxia, * corresponds to hypoxic treatment within genotype; #p < 0.05, *p < 0.05, **p < 0.01).
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FIGURE 5 | Increased extracellular matrix production in ABCG2 silenced mouse isolated cardiac fibroblasts under hypoxia. (A) Fluorescent
immunostainings indicate DAPI nuclear staining (blue), vimentin (red), ABCG2 (green) and an overlaid picture (merge) in a single–plane image of the mouse ventricle.
Arrows pointing out cardiac cells coexpressing ABCG2 and vimentin. Inset represents correspondent negative control. Scale bar = 20 µm. Graphs represent collagen
content as percentage in mouse primary fibroblasts derived from right ventricles (B), left ventricles (C) or from lungs (D) (n = 4), and show ABCG2 mRNA expression
in correspondent fibroblasts after transfection with control siRNA or siABCG2 (n = 3). Western blot gel pictures represent protein levels of ABCG2 in the respective
cells. Equalized loading was confirmed with GAPDH. Bar graphs represent values as means ± SD (*p < 0.05).
diastolic dysfunction. In the LV, elevated ventricular EDP is
a well-established indicator of heart failure and predictor of
mortality (Salem et al., 2006). When ABCG2 KO mice were
exposed to chronic hypoxia, we observed overt worsening of
biventricular diastolic function, as indicated by a significant
increase in EDP. Parameters describing early diastolic relaxation,
such as Tau or mindP/dt remained unchanged between
genotypes, collectively indicating a disturbed ventricular
function exclusively at the end of diastole. Such diastolic
changes can be caused by myocardial fibrosis, which may
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FIGURE 6 | Increased extracellular matrix production in ABCG2 silenced human primary cardiac fibroblasts under hypoxia. (A) Fluorescent
immunostaining indicate DAPI nuclear staining (blue) and ABCG2 (red) in a single–plane image of human cardiac fibroblast. Inset represents correspondent negative
control. Scale bar = 20 µm. (B) Bar graph shows ABCG2 mRNA expression in human primary cardiac fibroblasts after transfection with control siRNA or siABCG2
(n = 3). Western blot gel picture represents protein levels of ABCG2 in human primary cardiac fibroblasts. Equalized loading was confirmed with GAPDH. (C) Human
primary cardiac fibroblast proliferation, measured by incorporation of [3H]thymidine (n = 4). (D) Graph represents collagen content in human primary cardiac
fibroblasts, measured by hydroxyproline assay (n = 5). Bar graphs represent values as means ± SD (Interaction p corresponds to hypoxia·genotype interaction,
#corresponds to difference between genotypes in hypoxia, ##p < 0.01).
lead to functional changes of the ventricle (Rain et al., 2013).
Extracellular matrix deposition may provide a cardioprotective
effect by increasing myocardial structural resistance,
protecting against elevated pressure (Krenning et al., 2010).
However, excess fibrosis can decrease ventricular performance
(Chiao et al., 2012).
Elevated myocardial fibrosis is one of the main pathological
features associated with diastolic heart failure (Martos et al.,
2007; Rain et al., 2013). Furthermore, therapies ameliorating
ventricular fibrosis have been shown to improve diastolic
function (Brilla et al., 2000; Diez et al., 2002). Our study
shows that the hypoxia-induced structural changes in the
ventricular myocardium are markedly exaggerated in ABCG2
KOmice, suggesting that ABCG2 protects from hypoxia-induced
myocardial fibrosis. Interestingly, the same response pattern in
terms of diastolic dysfunction was found in the right and left
ventricle. This suggests that hypoxia per se and not hypoxia-
induced changes in afterload were the main cause for elevated
ventricular end-diastolic pressure and myocardial fibrosis in
ABCG2 KO animals.
In comparison to the WT animals ABCG2 KO mice has
elevated circulating levels of G-CSF, IL-1ra, CXCL1, and MCP-1
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FIGURE 7 | Increased ABCG2 expression in the stressed right ventricle of chronic hypoxic mice. Graph shows ABCG2 gene expression in right (A) - and left
ventricles (C) of mice exposed to chronic hypoxia (n ≥ 6 for each group). Subset (B,D) shows western blot analysis of ABCG2 in right- and left ventricle homogenates
respectively from mice after exposure to hypoxia for 4 weeks (n = 5 for normoxia, n = 7 for hypoxia). Signal densities were quantified using densitometric analysis.
(*p < 0.05).
in hypoxia (see Supplementary Figure S7). The elevation of these
fibrosis-associated cytokines (Sugano et al., 2005; Dobaczewski
and Frangogiannis, 2009; Vicenova et al., 2009; Sahin and
Wasmuth, 2013) might have also contributed to the increased
ventricular fibrosis, observed in ABCG2 KOmice under hypoxia.
Fibroblast-mediated matrix production may lead to increased
ventricular fibrosis which may result in elevated end-diastolic
pressure, as it can be also implied by a correlation of RVEDP
with right ventricular fibrosis. It is well accepted that the
excess fibrous tissue deposition in the heart is generally due
to increased extracellular matrix synthesis and/or proliferative
potential of cardiac fibroblasts (Camelliti et al., 2005). Herein
we also showed that cardiac fibroblasts do express ABCG2
transporter in the mouse heart. When these primary cells were
isolated from the ventricular tissue, they showed an increased
collagen production upon ABCG2 silencing under hypoxia.
Nevertheless, fibroblasts from mouse lungs did not show these
changes, which was in agreement with our in vivo observations
with increased ventricular fibrosis in KO mice under
hypoxia.
In line with the observations in the mouse ventricular
fibroblasts, we showed that human primary cardiac fibroblasts do
express ABCG2 and that its silencing significantly increased their
collagen production under hypoxia. This indicates that the results
obtained from the mouse model might be relevant for cardiac
fibrosis and diastolic dysfunction in humans. It has been shown
that ABCG2 provides cytoprotective effects under oxidative
stress, a condition very often associated to hypoxia (Maher et al.,
2014). Another elegant study suggested that ABCG2 protects
from hypoxia by preventing the accumulation of porphyrins,
explaining why the lack of ABCG2 increases the sensitivity to
hypoxia (Krishnamurthy et al., 2004). It is likely that in the
hypoxic heart, the lack of ABCG2 leads to an accumulation of
metabolic products, directly triggering collagen production in
cardiac fibroblasts.
In spite of these findings, the development of ABCG2
inhibitors is being expedited, because ABCG2 provides
multidrug resistance for tumor cells by active drug eﬄux,
thus the bioavailability of anticancer drugs can be improved
by co-administration with ABCG2 inhibitors (Breedveld
et al., 2006; Wu et al., 2008). Therefore, close attention to
the cardiac side effects of this new anticancer strategy is
warranted, especially in hypoxemic patients (Kessler et al.,
1996; Nieto et al., 2012; Campos-Rodriguez et al., 2013;
Laveneziana et al., 2013) and those with ischemic heart disease.
The present findings suggest, that ABCG2 inhibition might
cause adverse cardiac effects, if it were to be used in cancer
patients.
CONCLUSIONS
We provide evidence that loss of ABCG2 under hypoxia
leads to biventricular fibrosis and diastolic dysfunction, but
does not affect the development of pulmonary hypertension.
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In addition, targeting ABCG2 by siRNA in human primary
cardiac fibroblasts increased their collagen production under
hypoxia. Collectively, we have presented both in vivo and in
vitro findings strongly suggesting ABCG2 as an important player
for diastolic dysfunction under hypoxia. The use of ABCG2
inhibitors in cancer patients therefore might cause drug-induced
cardiotoxicity, particularly in hypoxemic patients or ischemic
heart disease.
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